Worthington & Caron, PC is proud to be lead sponsor of the
The 8th International Mesothelioma Symposium on Lung-Sparing Therapies
for Malignant Pleural Mesothelioma, where International Experts from around the world will meet to discuss
the latest treatment options for mesothelioma.
The 8th International Symposium will be held Saturday, September 29th at
the UCLA Meyer & Renee Luskin Conference Center in Los Angeles, California.
Course Chair, Dr. Robert Cameron, has over 30 years of experience treating
patients with malignant pleural mesothelioma. He has played a vital role
in the development of lung-sparing treatments including the pleurectomy/decortication
surgery and a number of adjuvant therapies. Dr. Cameron serves as Director of the
Comprehensive Mesothelioma Programs at UCLA Medical Center. He also serves as Scientific Advisor at the
Pacific Mesothelioma Center.
Dr. Cameron will be joined by leading mesothelioma experts who will highlight
recent advancements in mesothelioma treatment and cutting-edge research.
All physicians and nurses attending will receive continuing medical education
(CME) course credit.
*Patients and families are welcome and encouraged to attend.
For more information, and to register, click
here.
Presentations and Discussions:
-
Perioperative Immunotherapy: Surgery as Immunotherapy: Robert B. Cameron, MD, FACS
-
Mesothelioma Clinical Trials: Novel and Combination Systemic Therapies: Olga Olevsky, MD
-
An Exhaled Breath Biopsy Earmarks Exclusive Screening for Malignant Pleural
Mesothelioma: Kevin Lamote, PhD
-
Novel MRI Assessment of Mesothelioma Tumor Volume: Kevin G. Blyth, MD, MBchB, FRCP
-
Toxicities and Outcomes Using Whole Pleural Intensity – Modulated
Proton Therapy: Charles B. Simone II, MD
-
Understanding the Immune Response to Radiotherapy in a Dual Tumor Model
of Mesothelioma: Wesley Wilson, PhD Candidate
-
Integrative Molecular Characterization of Mesothelioma: Cancer Genome Atlas Project: Marc Ladanyi, MD
-
The Immune Microenvironment: Focus on Macrophages and T-Cells as Regulators
of Tumor Progression and Therapeutic Responses: Lisa M. Coussens, PhD
-
A Modified Measles Virus Against Mesothelioma: Oncolytic and Immunotherapeutic
Potential: Nicolas Boisgerault, PhD
-
Immunotherapy using Gene Modified Mesenchymal Stem Cells: Masahide Tone, PhD
-
Overcoming the Immunosuppressive Tumor Microenvironment of Murine Malignant
Mesothelioma: Mikihiro Kohno, MD, PhD
